Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma

Journal of Clinical Oncology

Volumn 15, Issue 3, 1997, Pages 1052-1062

  Du Bois, J S ^a   Trehu, E G ^a   Mier, J W ^a   Shapiro, L ^a   Epstein, M ^a   Klempner, M ^a   Dinarello, C ^a   Kappler, K ^a   Ronayne, L ^a   Rand, W ^a   Atkins, M B ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN G; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; PLACEBO; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ADVANCED CANCER; ARTICLE; CHIMERA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG TOLERANCE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; MELANOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING;

EID: 0031043250     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.3.1052     Document Type: Article

References (58)

1. Rosenberg SA, Lotze MT, Yang JC, et al: Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210:474-485, 1989
2. Dutcher JP, Creekmore S, Weiss GR, et al: A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477-485, 1989
3. Atkins MB, Sparano J, Fisher RI, et al: Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alpha-2b in advanced renal cell carcinoma. J Clin Oncol 11:661-670, 1993
4. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2. JAMA 271:907-913, 1994
5. Fyfe G, Fisher RI, Rosenberg SA, et al: Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688-696, 1995
6. Rosenberg SA, Mule JJ, Spiess PJ, et al: Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med 161:1169-1188, 1985
7. Talmadge JE, Phillips H, Schindler J, et al: Systemic preclinical study on the therapeutic properties of recombinant human interleukin 2 for the treatment of metastatic disease. Cancer Res 47:5725-5732, 1987
8. Thompson JA, Lee DJ, Welby Cox W, et al: Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial. Cancer Res 47:4202-4207, 1987
9. Bradley EC, Louie AC, Paradise CM, et al: Antitumor response in patients with metastatic renal cell carcinoma is dependent upon regimen intensity. Proc Am Soc Clin Oncol 8:133, 1989 (abstr 519)
10. Mier JW, Aronson FR, Numerof RP, et al: Toxicity of immunotherapy with interleukin-2 and lymphokine-activated killer cells. Pathol Immunopathol Res 7:459-476, 1988
11. Gaynor ER, Vitek L, Sticklin L, et al: The hemodynamic effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med 109:953-958, 1988
12. Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 4:486-498, 1989
13. Siegel JP, Puri RK: Interleukin-2 toxicity. J Clin Oncol 9:694-704, 1991
14. White RL, Schwartzentruber DJ, Gularia A, et al: Cardiopulmonary toxicity of treatment with high dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal cell carcinoma. Cancer 74:3212-3222, 1994
15. Samlowski WE, Ward JH, Craven CM, et al: Severe myocarditis following high-dose interleukin-2 administration. Arch Pathol Lab Med 113:838-841, 1989
16. Kragel AH, Travis WD, Steis RG. et al: Myocarditis or acute myocardial infarction associated with interleukin-2 therapy for cancer. Cancer 66:1513-1516, 1990
17. Atkins MB: Autoimmune disorders induced by interleukin-2 therapy, in Atkins MB, Mier JW (eds): Therapeutic Applications of Interleukin-2. New York, NY. Marcel Dekker, 1993, pp 389-408
18. Snydman DR, Gill M, Sullivan B, et al: Nosocomial sepsis associated with interleukin-2. Ann Intern Med 112:102-106, 1990
19. Pockaj BA, Topalian SL, Steinberg SM, et al: Infectious complications associated with interleukin-2 administration: A retrospective review of 935 treatment courses. J Clin Oncol 11:136-147, 1993
20. Numerof RP, Aronson FR, Mier JW: IL-2 stimulates the production of IL-1 alpha and IL-1 beta by human peripheral blood mononuclear cells. J Immunol 141:4250-4257, 1988
21. Mier JW, Vachino G, Van Der Meer JWM, et al: Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8:426-436, 1988
22. Gemlo BT, Palladino MA, Jaffe HS, et al: Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin-2 and lymphokine-activated killer cells. Cancer Res 48:5864-5871, 1988
23. Kasid A, Director EP, Rosenberg SA: Induction of endogenous cytokine-mRNA in circulating peripheral blood mononuclear cells by IL-2 administration to cancer patients. J Immunol 143:736-739, 1989
24. Heslop HE, Gottlieb DJ, Bianchi ACM, et al: In vivo induction of gamma interferon and tumor necrosis factor by interleukin-2 infusion following intensive chemotherapy or autologous bone marrow transplantation. Blood 74:1374-1380, 1989
25. Hibbs JB, Westenfelder C, Taintor R, et al: Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89:867-877, 1992
26. Ochoa JB, Curti B, Peitzman AB, et al: Increased circulating nitrogen oxides after human tumor immunotherapy: Correlation with toxic hemodynamic changes. J Natl Cancer Inst 84:864-867, 1992
27. Mier JW, Vachino G, Klempner MS, et al: Inhibition of interleukin-2-induced tumor necrosis factor release by dexamethasone: Prevention of an acquired neutrophil chemotaxis defect and differential suppression of interleukin-2-associated side effects. Blood 76:1933-1940, 1990
28. Fraker DL, Langstein HN, Norton JA: Passive immunization against tumor necrosis factor partially abrogates interleukin-2 toxicity. J Exp Med 170:1015-1020, 1989
29. Fraker DL, Thorn AK, Doherty GM, et al: Tumour necrosis factor mediates the survival benefit of interleukin-2 in a murine pulmonary metastases model. Surg Oncol 1:1-9, 1992
30. Thompson JA, Benyunes MC, Bianco JA, et al: Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells. Semin Oncol 20:46-51, 1993
31. Thompson J, Nemunaitis J, Vogelzang NJ, et al: Phase I study of CT1501R in cancer patients receiving high-dose interleukin- 2 (IL-2). Proc Am Soc Clin Oncol 13:299, 1994 (abstr 977)
32. G-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: Implications for the involvement of nitric oxide. Proc Natl Acad Sci USA 87:3629-3632, 1990
33. Dower SK, Smith CA, Park LS: Human cytokine receptors. J Clin Immunol 10:289-299, 1990
34. Smith CA, Davis T, Anderson D, et al: A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins. Science 248:1019-1023, 1990
35. Trehu EG, Mier JW, Du Bois J, et al: A phase I clinical trial of interleukin-2 (IL-2) in combination with the soluble TNF receptor IgG chimera (TNFR:Fc). Proc Am Assoc Cancer Res 36:496, 1995 (abstr 2953)
36. Klempner MS, Mier JW, Snydman DR, et al: Infections in patients receiving interleukin-2 immunotherapy: A double-blind placebo-controlled study of temafloxacin prophylaxis. Seventeenth International Congress on Chemotherapy, Berlin, Germany, August 23-28, 1991
37. Van der Meer JW, Endres S, Lonnemann G, et al: Concentrations of immunoreactive human tumor necrosis factor alpha produced by human mononuclear cells in vitro. J Leukocyte Biol 43:216-223, 1988
38. Schindler R, Mancilla J, Endres S, et al: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40-47, 1990
39. Porat R, Poutsiaka DD, Miller LC, et al: Interleukin-1 (IL-1) receptor blockade reduces endotoxin and borrelia burgdorferi-stimulated IL-8 synthesis in human mononuclear cells. FASEB J 6:2482-2486, 1992
40. Poutsiaka DD, Clark BD, Vannier E, et al: Production of interleukin-1 recpetor antagonist and interleukin-1 beta by peripheral blood mononuclear cells is differentially regulated. Blood 78:1275-1281, 1991
41. Hogan MM, Vogel SN: Measurement of tumor necrosis factor alpha and beta, in Coligan JE, Kruisbeek AM, Margulies DH, et al (eds): Current Protocols in Immunology. New York, NY, Wiley, 1993, pp 6.10.1-6.10-5
42. Committee on Nitrate and Alternative Curing Agents in Foods: Health effects of nitrate, nitrite, and N-nitroso compounds. Washington, DC, National Academy Press, 1981, pp 14-16
43. Bartholomew B: A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem Toxicol 22:541-543, 1984
44. Granger DL, Hibbs JB, Perfect JR, et al: Metabolic fate of L-arginine in relation to microbiostatic capability of murine macrophages. J Clin Invest 85:264-273, 1990
45. Klempner MS, Noring R, Mier JW, et al: An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322:959-965, 1990
46. Delellis RA, Sternberger LA, Mann RB, et al: Immunoperoxidase technics in diagnostic pathology: Report of a workshop sponsored by the National Cancer Institute. Am J Clin Pathol 71:483-488, 1979
47. Hsu SM, Raine L, Fanger H: Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580, 1981
48. Hibbs JB, Westenfelder C, Taintor R, et al: Evidence for cytokine-inducible nitric oxide synthesis from L-arginine in patients receiving interleukin-2 therapy. J Clin Invest 89:867-877, 1992
49. Fekade D, Knox K, Hussein K, et al: Prevention of Jarisch-Herxheimer reactions by treatment with antibodies against tumor necrosis factor alpha, N Engl J Med 335:311-315, 1996
50. Hechtman DH, Cybulsky MI, Fuchs HJ, et al: Intravascular IL-8: Inhibitor of polymorphonuclear leukocyte accumulation at sites of acute inflammation, J Immunol 147:883-892, 1991
51. Tilg H, Shapiro L, Vannier E, et al: Induction of circulating antagonists to IL-1 and TNF by IL-2 administration and their effects on IL-2-induced cytokine production in vitro. J Immunol 152:3189-3198, 1994
52. Fisher CJ, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl J Med 334:1697-1702, 1996
53. Suffredini AF, Reda D, Banks SM, et al: Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration, J Immunol 155:5038-5045, 1995
54. Evans TJ, Moyes D, Carpenter A, et al: Protective effect of 55- but not 75-kD soluble tumor necrosis factor receptor- immunoglobulin G fusion proteins in an animal model of gram-negative sepsis. J Exp Med 180:2173-2179, 1994
55. Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548-1561, 1993
56. Browning JT, Ngam-ek A, Lawton P, et al: Lymphotoxin beta, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 72:847-856, 1993
57. Crowe PD, VanArsdale TL, Walter BN, et al: A lymphotoxin-beta-specific receptor. Science 264:707-710, 1994
58. Bazzoni F, Beutler B: The tumor necrosis factor ligand and receptor families. N Engl J Med 334:1717-1725, 1996